Literature DB >> 8441738

Clinical pharmacology and toxicology of cocaine.

N L Benowitz1.   

Abstract

Cocaine abuse has produced a major epidemic health problem in North America in the 1980s. The abuse of cocaine is maintained by the drug's effects on brain reward systems, mediated at least in part by its dopaminergic action. The patterns and consequences of use are best understood by considering the pharmacokinetics (rapid absorption and delivery to the brain, relatively short half-life) and the pharmacodynamics (intense central and peripheral neural stimulation). Cocaine is used therapeutically as a topical and local anaesthetic. Toxicity occurs primarily in cocaine abusers, but also occasionally after therapeutic dosing. Medical complications reflect primarily excessive central nervous system stimulation and excessive vasoconstriction, the latter resulting in severe hypertension and/or organ ischaemia with associated organ injury. Most deaths that result from medical complications of cocaine intoxication are sudden and occur before medical intervention is possible. Other complications of cocaine abuse with severe personal and social consequences include traumatic deaths and injuries, and reproductive disturbances, as well as transmission of infectious diseases, especially AIDS. Cocaine addiction is clearly a problem, although the number of addicts is unknown. Pharmacologic treatment of cocaine addiction has as yet been unsuccessful. Psychosocial approaches remain the mainstay of therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8441738     DOI: 10.1111/j.1600-0773.1993.tb01331.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  39 in total

Review 1.  Pharmacotherapies for cocaine dependence.

Authors:  G O'Leary; R D Weiss
Journal:  Curr Psychiatry Rep       Date:  2000-12       Impact factor: 5.285

Review 2.  Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Authors:  Colin N Haile; James J Mahoney; Thomas F Newton; Richard De La Garza
Journal:  Pharmacol Ther       Date:  2012-01-31       Impact factor: 12.310

Review 3.  Bacterial cocaine esterase: a protein-based therapy for cocaine overdose and addiction.

Authors:  Diwahar Narasimhan; James H Woods; Roger K Sunahara
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

4.  Unexpected acetylcholinesterase activity of cocaine esterases.

Authors:  Claude J Rogers; Lisa M Eubanks; Tobin J Dickerson; Kim D Janda
Journal:  J Am Chem Soc       Date:  2006-12-06       Impact factor: 15.419

5.  KATP channels confer survival advantage in cocaine overdose.

Authors:  S Reyes; G C Kane; T Miki; S Seino; A Terzic
Journal:  Mol Psychiatry       Date:  2007-12       Impact factor: 15.992

6.  Effects of cocaine esterase following its repeated administration with cocaine in mice.

Authors:  Mei-Chuan Ko; Diwahar Narasimhan; Aaron A Berlin; Nicholas W Lukacs; Roger K Sunahara; James H Woods
Journal:  Drug Alcohol Depend       Date:  2009-02-13       Impact factor: 4.492

7.  Gastrointestinal haemorrhage associated with free-base (crack) cocaine.

Authors:  D A Fennell; S S Gandhi; B N Prichard
Journal:  Postgrad Med J       Date:  1995-06       Impact factor: 2.401

Review 8.  Respiratory toxicities from stimulant use.

Authors:  T E Albertson; W F Walby
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

9.  A thermally stable form of bacterial cocaine esterase: a potential therapeutic agent for treatment of cocaine abuse.

Authors:  Remy L Brim; Mark R Nance; Daniel W Youngstrom; Diwahar Narasimhan; Chang-Guo Zhan; John J G Tesmer; Roger K Sunahara; James H Woods
Journal:  Mol Pharmacol       Date:  2010-01-19       Impact factor: 4.436

10.  Cocaine and specific cocaine metabolites induce von Willebrand factor release from endothelial cells in a tissue-specific manner.

Authors:  William E Hobbs; Emily E Moore; Rebecca A Penkala; Douglas D Bolgiano; José A López
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-03-28       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.